Floatz logo

Sorafenib

Digestive System Neoplasms

Sichuan Cancer Hospital and Research InstituteSmall moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Digestive System Neoplasms cohort.

Asset / SponsorPhaseRating
Capecitabine
China Medical University, China
Phase 3BB
FLUOROURACILUM
Janssen Research & Development, LLC
Phase 3BB
Irinotecan
Pfizer
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2B
Linifanib
Abbott
Phase 3B

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →